INTRODUCTION
Pompe disease (Glycogen storage disease type II; acid maltase deficiency; MIM 232300) ranges in severity from a severe, infantile-onset cardiomyopathy to a late-onset myopathy, which is caused by deficiency acid α-glucosidase (GAA) varying from complete to partial. The current standard of care is enzyme replacement therapy (ERT) that requires frequent infusions and incurs high costs during life-long treatment. ERT in Pompe disease requires frequent infusions of rhGAA, often on a weekly basis, to correct glycogen storage in striated muscle via receptor-mediated uptake. The enzyme dosages required for ERT in Pompe disease are up to 100-fold greater than those for other lysosomal disorders [1] , which can be attributed at least in part to the poor uptake of recombinant human (rh) GAA by skeletal muscle associated with low abundance of the cation-independent mannose-6-phosphate receptor (CI-MPR) [2; 3] . The paucity of CI-MPR in adult mammalian muscle has underscored the concept that CI-MPR is limiting for ERT in Pompe disease.
Previously, low levels of CI-MPR were demonstrated in skeletal muscle of GAA-KO mice, specifically in muscles comprised primarily of type II myofibers [2] . Similarly, fibroblasts from a Pompe disease patient were deficient in CI-MPR recycling and the uptake of rhGAA was impaired [4] . Further evidence for the importance of CI-MPR was demonstrated by the increased efficacy of rhGAA modified to increase mannose-6-phosphate content [5] [6] [7] . The limiting effect of receptor-mediated uptake during ERT was confirmed by demonstrating that clenbuterol, a selective β 2 -agonist, enhanced CI-MPR expression and increased efficacy from ERT in mice with Pompe disease [3] .
Patients with late-onset Pompe disease have severe pulmonary insufficiency that may progress to respiratory failure while receiving ERT [8] . Many individuals with late-onset Pompe disease have residual gait abnormalities despite adherence to ERT, indicating a relative lack of response in leg muscles [9] . Even among the majority of infants with Pompe disease who respond well when treated early in life [10] , only partial efficacy from ERT has been observed. These children retain motor developmental delays and respiratory insufficiency [11] . Persistent neuromuscular involvement has included hypernasal speech and swallowing difficulties [12] , or strabismus and ptosis [13] , despite long-term ERT in infantile-onset Pompe disease. Many young children with Pompe disease require temporary or long-term assisted ventilation [11] .
Each of these above clinical abnormalities was refractile to ERT, indicating a need for improved therapy.
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Gene therapy has been developed in preclinical experiments to address the limitations of ERT, including partial efficacy and the need for frequent administration. The availability of novel adeno-associated virus (AAV) serotypes, including AAV serotype 8, has advanced liver-targeted gene therapy by improving liver tropism [14] . AAV2 vectors pseudotyped with AAV8 (AAV2/8) delivered genes to the liver approximately 100-fold more efficiently in mice, including GAA knockout (KO) mice, in comparison with traditional AAV2 vectors [14; 15] . Subsequently, a single administration of the AAV2/8 vector substantially corrected glycogen storage in the diaphragm and heart following the administration of a lower number of vector particles (1x10 11 vector particles (vp), approximately 4x10 12 vp/kg body weight) [16] . The aforementioned AAV vector contained a liver-specific regulatory cassette that induced immune tolerance to GAA, which was dependent upon activation of regulatory T cells [17] . depot for the continuous secretion of GAA into the bloodstream [16; 22; 23] . Given the evidence that CI-MPR expression was crucial to efficacy from GAA replacement in Pompe disease, we chose to enhance CI-MPR levels in GAA-KO mice in combination with liver-targeted gene therapy. This strategy differs from previous attempts to address the limiting role of CI-MPR expression during ERT in Pompe disease, which increased the mannose-6-phosphate content of rhGAA [6; 24] . We wished to increase CI-MPR in skeletal muscle to demonstrate the dependence of biochemical correction upon receptor-mediated uptake of GAA.
Therefore, the vector-transduced liver depot was enhanced by the addition of a selective β2-agonist drug,
clenbuterol. Clenbuterol was previously demonstrated to increase the expression of the insulin-like growth factor (Igf) 2 receptor (identical to CI-MPR) in muscle of mice [25] .
In the current study clenbuterol was administered in combination with an AAV vector containing a liver-specific regulatory cassette (AAV-LSPhGAA). These new experiments demonstrated that clenbuterol and albuterol, selective β 2 -agonist drugs, enhanced CI-MPR expression and increased efficacy from a liver depot in GAA-KO mice, thereby confirming the efficacy of CI-MPR up-regulation during gene replacement therapy in Pompe disease [3] .
MATERIALS AND METHODS

Generation of muscle-specific CI-MPR-KO and DKO mouse models:
CI-MPR-KO mice were generated using a muscle-specific promoter (muscle creatine kinase; CK) and the cre/loxP conditional knock out system as described previously [28] . The muscle-specific CI-MPR-KO mice were crossed with GAA-KO mice to generate muscle-specific CI-MPR-KO/GAA-KO ("double KO"; DKO) mice. This mouse colony was subsequently screened to be GAA -/-, M6PR flox/flox and MCK-Cre positive. DKO mice were genotyped and bred as described [3] . At the indicated time points post-injection, tissue samples were obtained and processed as described below. All animal procedures were done in accordance with Duke University Institutional Animal Care and Use Committee-approved guidelines.
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Rotarod testing was performed as described [15] . Wirehang testing was performed with a 0.5 cm mesh hardware cloth fixed to an 8 by 10 inch frame. Mice were placed on the wire mesh, which was slowly inverted 6 inches over a cage containing paper bedding. The latency, or time until the mouse fell off of the wire mesh, was recorded. Western blotting of hGAA was performed as described using the hGAA monoclonal antibody (courtesy of Genzyme Corp., Framingham, MA) and the CI-MPR antibody (catalog number GTX28093; Gene Tex, Irvine, CA) [22] . GAA activity and glycogen content were analyzed as described [15] . Histologic processing and staining of brain was performed using a modified paraffin processing and staining protocol as previously described [29] .
Statistical analyses
Comparison of two groups was assessed by a homoscedastic Student T-test. A p-value <0.05 was considered to be statistically significant.
RESULTS
Enhancement of CI-MPR expression and efficacy from gene therapy with β2-agonist administration
The liver was transduced by administering a low number of AAV-LSPhGAA vector particles (2x10 10 vp; 8x10 11 vp/kg) to two groups of 3 month-old male GAA-KO mice, and clenbuterol (30 mg/l in drinking water) was administered to one group of 3 month-old vector-injected male mice. Neuromuscular function was evaluated by Rotarod testing, which quantifies the ability of mice to walk on a rotating rod and previously correlated with the biochemical correction of striated muscle in GAA-KO mice [15] . The effect of clenbuterol was evident, when Rotarod testing was performed 4 weeks following vector administration. The 
Long-term efficacy from β2-agonist treatment as an adjunct to gene therapy
The next experiments were designed to determine if the added efficacy from β2-agonist therapy would be sustained during longer-term treatment. AAV-LSPhGAA was administered to two groups of adult GAA-KO mice at a slightly higher particle number (4x10 10 vector particles), and clenbuterol (30 mg/l) was administered to one group. When mice were evaluated serially by Rotarod testing a gradual increase in latency was observed for each vector-treated group from 1 to 12 weeks ( Figure 3A) . Latency increased for mice treated with clenbuterol and vector, in comparison with either vector alone or with no treatment.
Biochemical correction was evaluated in striated muscle, and surprisingly, GAA activity was not increased following combination therapy ( Figure 3B ). However, biochemical correction with the vector was enhanced
by clenbuterol administration, as demonstrated by significantly lower glycogen content in the diaphragm, quadriceps, gastrocnemius, and EDL, in comparison with vector alone ( Figure 3C ). Combination therapy also significantly lowered the glycogen content of the cerebrum, in comparison with no treatment ( Figure   3C ). Thus, Rotarod and glycogen content data demonstrated the long-term efficacy from adjunctive therapy with clenbuterol.
A second β2-agonist drug, albuterol (30 mg/l in drinking water), was administered to an equivalent group of vector-treated mice, to determine if the beneficial effect might be achieved with a β2-agonist other than clenbuterol. Rotarod latency was not increased following administration of the combined albuterol and vector administration ( Figure 3D ). Biochemical correction was evaluated in striated muscle and the brain and GAA activity was not higher following combination therapy, in comparison with vector alone ( Figure 3E ).
However, combination therapy significantly reduced the glycogen content of the diaphragm and of the cerebrum, in comparison with vector alone ( Figure 3F ). Thus, clenbuterol was more effective than albuterol, because clenbuterol significantly lowered glycogen content in the quadriceps and EDL of vector treated mice, whereas albuterol did not ( Figure 3C versus Figure 3F ). 
Muscle-specific knockout of CI-MPR impaired the response to AAV-LSPhGAA with clenbuterol
The impact of CI-MPR depletion upon the liver depot strategy was further evaluated by administering AAV-LSPhGAA to DKO mice that lacked CI-MPR expression in striated muscle. The key role of CI-MPR was previously suggested by the lack of efficacy for either ERT [3] or muscle-restricted gene therapy [30] in DKO mice. The vector particle number administered was reduced to a low dose (2x10 10 vp) [31] , in order to evaluate the effect of CI-MPR depletion upon low dose gene therapy ( Figure 5 ). The GAA activities of muscles from DKO and GAA-KO mice were similarly elevated following AAV-LSPhGAA administration, in comparison with GAA-KO mice treated similarly ( Figure 5A ), which suggested that another receptor in addition to CI-MPR was involved in GAA uptake into DKO muscle from the blood.
Given the lack of effect upon muscle GAA activity from depleting CI-MPR in DKO mice, it might be assumed that gene therapy had circumvented the effect of CI-MPR deficiency in the muscle of DKO mice.
However, the clearance of glycogen from the skeletal muscle of DKO mice was impaired following administration of AAV-LSPhGAA ( Figure 5B ). The residual glycogen content in the diaphragm, gastrocnemius, soleus, and EDL was significantly higher in DKO mice, in comparison with GAA-KO mice, when analyzed 18 weeks following vector administration ( Figure 5B ; Table 1 ).
The mechanism of β2-agonist treatment was further evaluated in DKO mice, which should have a lesser response to combination treatment if CI-MPR modulated the effect of β2-agonists. The vector dose was increased 5-fold relative to the above-mentioned experiment in DKO mice (to 1x10 11 vp), which should increase the likelihood of achieving efficacy ( Figure 5 ). Rotarod latency was not significantly greater in DKO mice following combined treatment, in comparison with vector alone or mock treatment (not shown).
Biochemical correction was evaluated in both the heart and skeletal muscle of DKO mice. GAA activity was not significantly greater following combination treatment, in comparison with vector alone ( Figure 5C ). The glycogen content of the diaphragm was not reduced following combination treatment, in comparison with mock treatment; however, the glycogen content of the diaphragm increased slightly following administration of vector alone, in comparison with mock treatment ( Figure 5D ). Therefore the reduced glycogen content of the diaphragm from combination therapy, in comparison with vector alone, was from random variation. In contrast, glycogen content of the quadriceps of DKO mice was not reduced by combination therapy, in comparison with vector alone ( Figure 5D ). Thus, despite the markedly higher GAA activity following vector administration ( Figure 5C ), gene therapy with or without clenbuterol treatment did not consistently reduce glycogen content in the major muscles of DKO mice ( Figure 5D ).
The potential role of mitochondrial proliferation in the enhanced efficacy from β2-agonist treatment was evaluated by analyzing cytochrome C oxidase activity in the quadriceps of GAA-KO mice following combination treatment [32] . Clenbuterol treatment slightly reduced cytochrome c oxidase activity and albuterol had no effect, in comparison with vector alone ( Figure 5E ). Therefore, the lack of enhanced glycogen reduction in DKO mice supported the hypothesis that β2-agonist treatment was effective due to CI-MPR over-expression.
Enhanced muscle strength and biochemical correction of skeletal muscle from adjunctive clenbuterol in elderly GAA-KO mice
Combination therapy was evaluated in mice with advanced Pompe disease, because elderly GAA-KO mice were particularly resistant to correction with AAV vector-mediated gene therapy [26; 27] . Groups of 12 month-old GAA-KO mice of both sexes were treated with a high dose of AAV2/8-LSPhGAA (1x10 (Figure 6C ; p<0.07). Clenbuterol alone did not reduce the glycogen content of heart or skeletal muscle in elderly GAA-KO mice (not shown).
DISCUSSION
The upregulation of CI-MPR enhanced the response to gene therapy in GAA-KO mice treated with clenbuterol (and to a lesser extent albuterol), based upon increased Rotarod latency and lower glycogen content in skeletal muscle. Importantly, the glycogen content was reduced in the diaphragm and multiple skeletal muscles by either short-term or long-term combination therapy with an AAV vector and β2-agonist.
The improved biochemical correction in diaphragm represents a critical component of efficacy, both due to the respiratory involvement in Pompe disease and to the resistance of this muscle to correction with gene therapy [33] . Both neuromuscular function and the biochemical correction of skeletal muscles were improved following treatment of GAA-KO mice with selective β 2 -agonist drugs and gene therapy.
Combination therapy achieved partial efficacy in elderly GAA-KO mice, which have been refractile to gene therapy [26; 27] . We confirmed that the effect of clenbuterol depends upon CI-MPR up-regulation, because combination therapy was much less efficacious in DKO mice than in GAA-KO mice. Part of the effect from clenbuterol might stem from improved trafficking of GAA to lysosomes, rather than improved uptake, because glycogen content was reduced by the addition of clenbuterol without further elevating GAA activity ( Figure 1C-D) .
The dependence of efficacy from gene therapy upon CI-MPR-mediated uptake of GAA was emphasized by the lack of glycogen clearance from the muscle of DKO mice that lacked CI-MPR in muscle, even when GAA activity was markedly higher following administration of a 5-fold higher dosage of vector Clenbuterol has demonstrated hypertrophic effect upon skeletal muscle in rodent models by increasing expression of Igf-1 and Igf-2 [34; 35] . Clenbuterol administration was associated with greater muscle weight in the limb muscles, including gastrocnemius as seen in the current study [36] [37] [38] . The expression of the Igf-2 receptor, identical to CI-MPR, was higher in the hypertrophied masseter muscle following clenbuterol treatment [25] . Taken together, these data suggest that the mechanism for enhanced efficacy from replacement therapy by the addition of clenbuterol is the expression of CI-MPR by type II myofibers that were previously unresponsive to ERT [2; 24] . Consistent with this hypothesis, we demonstrated greater expression of CI-MPR in the EDL [3] .
The treatment of Pompe disease might be enhanced by adjunctive therapies that improve the response to GAA replacement, such as β2-agonists; however, the translation of rodent studies to clinical trials will depend upon the response of humans to these drugs. One critical factor will be the effective concentration of β2-agonists. Limited data are available, but the effective concentration (EC50) for clenbuterol was lower for humans and other higher mammals than for rodents. For example, the EC50 for clenbuterol with regard to the relaxation of rat smooth muscle was approximately 10-fold higher than the EC50 for equine or human smooth muscle [39] [40] [41] . Furthermore, the EC50 in horses and humans were similar to the EC50, when clenbuterol was dosed as a bronchodilator [40; 42] . These studies suggest that Page 14 lower dosages of clenbuterol might be effective in humans, in comparison with the high dosages utilized in rodent studies.
The underlying hypothesis for this study stated that increased CI-MPR expression would improve the response to GAA replacement, which hinges upon the increased insulin-like growth factor signaling and muscle hypertrophy from treatment with β2-agonists [25] . Although the vast majority of data regarding the effects of β2-agonists upon muscle has been obtained from studies in rodents, several clinical trials have indicated that β2-agonists are well-tolerated and promote muscle hypertrophy in humans. Several studies of β2-agonists in patients with neuromuscular demonstrated increased muscle strength and/or increased muscle mass. The largest study enrolled 90 patients with fascioscapulohumerol muscular dystrophy (MD) in a randomized, placebo-controlled trial of albuterol for one year, and revealed increased grip strength and lean body mass [43] . Increased lean body mass reflected increased muscle mass. Similarly, a study in which boys with Duchenne MD took albuterol for 12 weeks demonstrated increased quadriceps strength [44] . A larger follow-up study in patients with Duchenne MD revealed increased lean body mass following albuterol treatment [45] . A study of clenbuterol in patients with chronic heart failure revealed that lean muscle mass increased after 12 weeks [46] . A study of clenbuterol in 14 subjects with amyotrophic lateral sclerosis revealed increased muscle strength and improved pulmonary function testing, reflected by forced vital capacity, at the three and 6 month time points [47] . Finally, a small study in which patients with lateonset Pompe disease took albuterol for three years revealed that the drug was well-tolerated and each patient had increased performance on muscle function testing [48] . Increased muscle mass or strength in the aforementioned studies could reflect muscle hypertrophy and increased CI-MPR expression from β2-agonist treatment in humans. The possibility that β2-agonists achieve muscle hypertrophy at standard dosages supports the further translation of adjunctive therapy with ERT for Pompe disease in clinical trials.
The blood brain barrier remains a significant obstacle to therapy in lysosomal storage disorders, either in the form of ERT or gene therapy. It has been hypothesized that low phosphorylation of lysosomal enzymes and low expression of the CI-MPR prevented the uptake of lysosomal enzymes and biochemical correction of the brain in lysosomal storage disorders [49] . The current study demonstrated that β2-agonist treatment increased CI-MPR expression and enhanced the efficacy from the administration of a low number Page 15
of AAV vector particles, in contrast with the administration of clenbuterol alone that failed to achieve significant biochemical correction. Clenbuterol crossed the blood-brain barrier to affect the brain in rodents [50] . We demonstrated a unique effect upon the brain by demonstrating increased CI-MPR expression in the cerebrum following 4 weeks of adjunctive clenbuterol treatment. We confirmed that β2-agonist treatment increased CI-MPR levels and enhanced the biochemical correction of the brain from GAA replacement with gene therapy, which was consistent with results from a recent study of β2-agonist treatment in combination with ERT in mice with Pompe disease [51] . Consistent with the latter study, glycogen content of the cerebellum was reduced by adding adjunctive β2-agonist treatment (Figure 1 ). By 18 weeks following vector treatment the differences between combination therapy and vector alone were blurred, although combination therapy reduced the glycogen content in the cerebrum ( Figure 3C ) and glycogen staining in the cerebellum ( Figure 4C ). Recently an in vitro model of the blood-brain barrier revealed that arylsulfatase A uptake across the barrier was partially dependent upon CI-MPR, further validating the role of CI-MPR in the entry of lysosomal enzymes into the central nervous system [52] . These data support the possibility that β2-agonists might be a useful adjunctive therapy for other lysosomal storage disorders such as mucopolysaccharidoses that feature severe brain involvement [53] . The efficacy of GAA replacement therapy was enhanced by increased CI-MPR expression from β2-agonist administration. This preclinical data promises that the response to ERT in Pompe disease might be improved by treatment with clenbuterol or a similarly active β 2 -agonist drug. Furthermore, it is likely that adjunctive therapy to increase CI-MPR expression will facilitate the translation of gene therapy for Pompe disease to clinical applications, which could potentially provide curative therapy for this devastating condition. 
